Cerus appoints Dr. Hua Shan to Board of Directors effective July 1, 2022

CERUS CORP

Dr. Hua Shan, Medical Director of Transfusion Medicine at Stanford, joins Cerus Board effective July 1, 2022.
She brings over 25 years of transfusion medicine experience, including expertise in Chinese blood bank practices.
Receives $45k annual cash retainer and initial equity grants valued at $150k in options and $150k in RSUs, vesting over 3 years.
Appointment supports Cerus's JV to bring INTERCEPT Blood System to China and global expansion.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Hua Shan

Director

CERS · CERUS CORP

Effective: 2022-07-01
Filed: July 5, 2022, 7:59 PM ET

the Board extended an offer to join the Board to Hua Shan, MD, PhD, and on June 30, 2022, Dr. Shan accepted such offer to join the Board, effective July 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Hua Shan was appointed as Director at CERUS CORP.

Action: appointed
Role: Director

Exact text from the filing

the Board extended an offer to join the Board to Hua Shan, MD, PhD, and on June 30, 2022, Dr. Shan accepted such offer to join the Board, effective July 1, 2022.

View on SEC.gov

CERUS CORP filing history →

Source: SEC EDGAR

accession 0001193125-22-187995

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.